Emmanuel Papadakis from Deutsche Bank retains his negative opinion on the stock with a Sell rating. The target price is unchanged and still at CHF 250.
In his latest research note, analyst Emmanuel Papadakis confirms his positive recommendation. The broker Deutsche Bank is keeping its Buy rating. The target price remains set at GBX 1700.
As Novo Nordisk and Eli Lilly duke it out in the weight-loss drug market with Ozempic, Wegovy and Mounjaro, drug company competitors plan to join the fray.
As Novo Nordisk and Eli Lilly duke it out in the weight-loss drug market with Ozempic, Wegovy and Mounjaro, drug company competitors plan to join the fray.
Analyst Emmanuel Papadakis from Deutsche Bank research considers the stock attractive and recommends it with a Buy rating. The target price is unchanged at GBX 1700.